Stocks & Investing
Stocks and Investing
Stocks and Investing
Wed, April 3, 2024
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
Dae Gon Ha Maintained (VERV) at Strong Buy with Decreased Target to $40 on, Apr 3rd, 2024
Dae Gon Ha of Stifel, Maintained "Verve Therapeutics, Inc." (VERV) at Strong Buy with Decreased Target from $56 to $40 on, Apr 3rd, 2024.
Dae has made no other calls on VERV in the last 4 months.
There is 1 other peer that has a rating on VERV. Out of the 1 peers that are also analyzing VERV, 0 agree with Dae's Rating of Hold.
This is the rating of the analyst that currently disagrees with Dae
- Luca Issi of "RBC Capital" Reiterated at Buy and Held Target at $35 on, Wednesday, February 28th, 2024
